In short. What approval covers, what the labelling must state, and why some surfaces left some markets while remaining available in others.
Key points
- One is a condition of being allowed to sell the device, and the other is marketing copy.
- Where a technology claim and a labelled statement point in different directions, the labelled statement is the one that had to be accurate to a regulator’s standard.
Regulation of implant technology is attached to devices rather than to ideas, and the labelling is where the technology claims meet their hardest test. Reading the two together explains most of what happens when a surface is restricted in one country and remains available in another.
Approval is specific to a device
An authorisation names an indication, a population and a jurisdiction, and it covers the device as submitted — a particular shell, surface, fill and shape. A change to any of those generally means the product is assessed afresh rather than treated as the previous device with an improvement added. That is why there is no approved class called a generation: the numbering used in marketing has no counterpart in a device register.
What the labelling has to say
Where the requirement applies, the label carries a statement that the implant is not a lifetime device and that rupture and capsular contracture are recognised risks, together with an identification of the surface and the fill. These are conditions of approval rather than optional disclosures, which makes the label the most reliable short description of a device that exists. A brochure that omits them is not describing a different device; it is describing the same device selectively.
The label is authorised; the brochure is written
One is a condition of being allowed to sell the device, and the other is marketing copy. Where a technology claim and a labelled statement point in different directions, the labelled statement is the one that had to be accurate to a regulator’s standard.
Why markets diverge
Regulators act on the balance of evidence available to them, and different regulators weighing the same signal have reached different conclusions. Several have restricted or withdrawn rougher-surfaced implants over the lymphoma association; others permit them with conditions attached. A restriction is a decision about availability in a market rather than a finding about every person who has such a device, and continued availability elsewhere is not a finding that the association does not exist. Where regulators differ, this review reports the difference rather than choosing the version that suits a conclusion.
What the divergence costs a reader
It means that a statement citing an approval is incomplete unless it names the authority, the market and the task or indication. It also means that the same product name can sit in different classes in different places, so a comparison between two clinics in two countries can be comparing two different regulatory situations without either of them saying so.
Three questions about a regulatory statement
- Which authority authorised it, in which market, and for which indication?
- What does the current label state about rupture, contracture and service life?
- Is this surface or device restricted anywhere, and if so, on what evidence did that regulator act?
Approval tells you what a manufacturer had to demonstrate. It does not tell you what the device will do for you, and the difference between those two questions is the subject of the rest of this site.
Frequently asked questions
Does approval cover a device or a technology?
A device. Approval is granted for a defined indication, in a defined population, in a defined jurisdiction, and the combination of shell and fill is part of what was authorised. Changing either generally means the device is assessed as a new device rather than as an updated version of the old one.
What must the labelling state?
In the markets that require it, the label states that the implant is not a lifetime device and that rupture and capsular contracture are recognised risks, and it identifies the surface and the fill. Those statements are conditions of the approval rather than marketing choices.
Why are textured implants restricted in some countries but not others?
Because different regulators weighed the same evidence differently. Several have restricted or withdrawn rougher-surfaced devices over the lymphoma association, while others permit them with conditions. Divergence between regulators is common and it does not by itself settle which decision was right.
Risks & Limitations
- No generation of implant is a lifetime device, and a proportion will need removal or replacement at some point.
- Rougher surfaces carry an established association with a rare lymphoma of the tissue around the implant.
- Rupture can occur without symptoms, so surveillance over time is advised whatever device is in place.
- Capsular contracture is a recognised risk and no surface has eliminated it.
- A design feature is a modification with a reason behind it, not a demonstrated improvement in outcome.
When to Seek Care
- A change in the shape or size of a breast, or a new lump — have it assessed by a clinician.
- Swelling that comes and goes, or a fluid collection around an implant.
- Persistent pain or firmness around an implant, or a new and persistent symptom.
- Contact the service that holds your records, or the hospital’s outpatient channels, rather than relying on a website.
References & Further Reading
- U.S. Food and Drug Administration (FDA) — approved breast implant labelling and safety communications
- European Medicines Agency (EMA) and national regulators — breast implant assessment reports and restrictions
- National Medical Products Administration (NMPA, China) — approved devices and their indications
- World Health Organization (WHO) — classification of tumours of the breast, including implant-associated lymphoma
- Chinese Medical Association Plastic Surgery Branch — clinical guidance
This page is patient education, not medical advice, and it does not cite individual studies. It reviews evidence and regulation; it is not a booking page and does not recommend a treatment. Discuss your own case with a qualified clinician. To ask a question about this review, see Contact & Consultation.